Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials

Puntos clave

• Iza-bren significantly enhances response rates in EGFR-mutated non-small cell lung cancer (NSCLC), indicating effectiveness.
• In combined phase I and phase II trials, the treatment achieved a notable response rate of 50%, showcasing robust clinical potential.
• The assessment utilizes pooled data from trials evaluating the efficacy of a first-in-class bispecific antibody drug conjugate.
• This analysis highlights the therapeutic promise of Iza-bren for managing EGFR-mutated NSCLC, though ongoing studies are needed.